Supplementary Table from Effects of Infection-Induced Fever and the Interaction with <i>IL6</i> rs1800796 Polymorphism on the Prognosis of Breast Cancer
Hengming Ye(Guangdong Medical College), Zefang Ren(Sun Yat-sen University), Xiaoming Xie(Sun Yat-sen University Cancer Center), Zhuozhi Liang(Sun Yat-sen University), Ying Lin(Sun Yat-sen University), Qian-Xin Chen(Sun Yat-sen University), Yun-Qian Li(Sun Yat-sen University), Qiang Liu(China Agricultural University), Lu-Ying Tang(Sun Yat-sen University)
Cited by 0
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week
|Nature Communications|2021|261
N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer
|Nature Communications|2022|214